Characterization of Immune Genotypes and Antibody Profiles to Foster the discoVERY of diagnosticbioMARKERS of Liver Cancer Development

Launched by CENTRO DI RIFERIMENTO ONCOLOGICO - AVIANO · Dec 2, 2024

Keywords

ClinConnect Summary

This clinical trial is studying how certain genetic factors and immune responses might help identify early signs of liver cancer (HCC) in patients who have chronic Hepatitis C virus (HCV) infection. Although treatments have improved the ability to eliminate the virus, patients with HCV still need to be monitored closely for the risk of developing liver cancer. The researchers are looking at specific markers in the blood, such as antibodies and genetic expressions, that could indicate an increased risk of HCC even years before it is diagnosed.

To be eligible for the trial, participants must be at least 18 years old and have chronic HCV infection, fibrosis (scarring of the liver), cirrhosis, or liver cancer related to HCV. Those who have received treatment for other cancers or have certain immune system issues would not be included. Participants will be asked to provide blood samples and answer some questions about their health. The goal is to find better ways to detect liver cancer early, which can lead to more effective treatment options. This is an important step in improving outcomes for patients with HCV.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients aged ≥18 years with the presence of chronic infection, fibrosis, cirrhosis or HCV- associated HCC
• • Patients able to understand and willing to sign the of informed consent
• • Patients to answer the questions in the questionnaire of enrollment
• Exclusion Criteria:
• • Treatment for other oncological diseases
• • Immunodepression congenital or acquired (HIV, organ transplantation, pharmacological)